GlobeNewswire

ICU Medical Announces Third Quarter 2026 Results and Reaffirms Fiscal Year 2026 Guidance, Expecting Results at the High End of Range
05/11/2026
SAN CLEMENTE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
FocalTherics™ Reports Third Quarter 2026 Financial Results
05/11/2026
45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date FocalTherics™ Reports Third Quarter 2026 Financial Results 45% Revenue Increase and 44% Growth in U.S. Procedure Volume Year-to-date AUSTIN, [...]
Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates
05/11/2026
Continued progress toward starting SC451 Phase 1/2 trial in type 1 diabetes Continued progress toward starting clinical study for SG293 in non-Hodgkin lymphoma Announced follow-on publication in The New England Journal [...]
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/11/2026
CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late-stage clinical pharmaceutical company dedicated to the discovery, development and commercialization [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Troisième Trimestre 2026
05/11/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Troisième Trimestre 2026 Le chiffre d’affaires net mondial s’est élevé à 9,2 millions d’euros, porté par une croissance séquentielle [...]
Nyxoah Reports Third Quarter 2026 Financial and Operating Results
05/11/2026
REGULATED INFORMATION Nyxoah Reports Third Quarter 2026 Financial and Operating Results Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand [...]
Mobia Medical Reports Third Quarter 2026 Financial Results
05/11/2026
Delivers revenue growth of 73% in the third quarter and raises full year 2026 revenue guidance AUSTIN, Texas, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a medical device company redefining [...]
Quantum-Si Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
Proteus™ remains on track for anticipated Q2 2027 commercial launch BRANFORD, Conn., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics [...]
Solésence To Report Third Quarter 2026 Financial Results and Host a Conference Call on November 12
05/11/2026
ROMEOVILLE, Ill., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
MacroGenics to Participate in Upcoming Investor Conferences
05/11/2026
ROCKVILLE, MD, Nov. 05, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, [...]
Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
05/11/2026
DOYLESTOWN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
05/11/2026
BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced [...]
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results
05/11/2026
Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully [...]
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results
05/11/2026
CANTON, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, [...]
Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
05/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies [...]
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
05/11/2026
CERRITOS, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Starling Oncology, Inc. (NASDAQ: STLN) (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported [...]
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates
05/11/2026
Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre [...]
TerrAscend Reports Third Quarter 2026 Financial Results
05/11/2026
Q3 2026 Net Revenue of $68.2 Million, Up 4.8% Year-Over-Year Q3 2026 Gross Profit Margin of 52.3%, Up 20 Basis Points Year-Over-Year Q3 2026 Net Cash Provided from Continuing Operations of $8.8 Million, Representing 17. [...]
Nephros Announces Strong Third Quarter 2026 Financial Results
05/11/2026
Year Over Year Net Revenue Growth of 18% and Core Programmatic Revenue Growth of 8% for the Three Months Ended September 30, 2026 SOUTH ORANGE, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nephros, Inc. (Nasdaq: NEPH), a [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum